LGVN9:20 AMNew Phase 2a Clinical Data Analysis of Stem Cell Therapy Laromestrocel in Mild Alzheimer’s Disease Accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference (AAIC)longeveron.com
LGVN9:20 AMLongeveron Granted Small or Medium-sized Enterprise (SME) Status by the European Medicines Agency (EMA)longeveron.com
LGVN4:05 PMLongeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering Approach and 2026 Key Prioritieslongeveron.com
LGVN4:05 PMLongeveron Announces 2026 First Quarter Financial Results and Provides Business Updatelongeveron.com
LGVN9:10 AMLongeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)longeveron.com
LGVN4:05 PMLongeveron Announces Constructive Type C Meeting with U.S. FDA Ahead of Data Readout for ELPIS II Phase 2b Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS)longeveron.com
LGVN4:15 PMLongeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026longeveron.com